The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a B7-H3-targeted antibody-drug conjugate (ADC) co-developed by China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) and the UK pharmaceutical major GSK (NYSE: GSK). This PRIME designation follows Breakthrough Therapy Designations (BTDs) received in the United States and China in August and October of this year, respectively.
HS-20093: A Novel B7-H3-Targeted ADC for Relapsed ES-SCLC
HS-20093 is currently being tested in patients with relapsed extensive-stage small-cell lung cancer (ES-SCLC). This innovative investigational B7-H3-targeted ADC consists of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. The PRIME designation highlights the potential of HS-20093 to address unmet medical needs for patients with ES-SCLC.
GSK’s Licensing Deal with Hansoh Pharmaceutical
GSK obtained ex-Greater China rights to HS-20093 in a significant USD 1.7 billion licensing agreement with Hansoh back in December 2023. This collaboration underscores the global interest in advancing the development and commercialization of novel targeted therapies for cancer treatment.-Fineline Info & Tech
